3 Importantly, however, GOG-209 required patients to be chemotherapy-naive, which calls into question the potential benefit of a combination platinum re-challenge in patients whose disease had progressed on prior systemic chemotherapy. 2 GOG-209 then demonstrated carboplatin and paclitaxel to be noninferior to cisplatin, doxorubicin, and paclitaxel, with less toxicity, ushering in an era in which carboplatin and paclitaxel became the preferred chemotherapy regimen for patients with advanced-stage or recurrent endometrial cancer. Despite improvements in progression-free survival (PFS) and overall survival (OS), this regimen was associated with significant treatment-related toxicity. 1 Given the rising incidence and mortality, with emerging data suggesting that endometrial cancer may overtake ovarian cancer as the most lethal gynecologic malignancy, there is a clear need to identify effective treatment options for patients with advanced-stage or metastatic disease.įollowing a series of clinical trials examining radiation therapy as well as single and doublet chemotherapy regimens, the GOG-177 trial from the Gynecologic Oncology Group identified cisplatin, doxorubicin, and paclitaxel as an effective triplet combination. Although most patients with endometrial cancer have localized disease, with a 5-year relative survival rate of 94.9%, patients with distant disease have a 5-year relative survival rate of approximately 18.4%. Given the recent advancements in immune oncology approaches, we review regimens approved by the US Food and Drug Administration as well as the interim results of ongoing phase 3 clinical trials.Įndometrial cancer is the most common gynecologic cancer in the United States. More recently, the identification of molecular subtypes has transformed the treatment paradigms for patients with endometrial cancer, especially in the immunotherapeutic arena. Traditionally, systemic treatment has included combination platinum- and taxane-based chemotherapy. Abstract: Endometrial cancer is the most common gynecologic cancer in the United States, with a rising incidence and mortality.
0 Comments
Leave a Reply. |